Skip to main content

The SPIRIT-P3 trial

Results published: Continuing ixekizumab superior to withdrawal in stable PsA

Monday 11 November: 14:30–16:00, Hall B1, Georgia World Congress Center, Atlanta, USA

Presenter: Laura Coates, University of Oxford, UK

This phase IIIb study involved patients with psoriatic arthritis who achieved minimal disease activity during 36 weeks of open-label treatment with the interleukin-17A inhibitor ixekizumab, and were then randomly assigned to continue receiving ixekizumab or switch to placebo for the remainder of the 2-year study.

Coates will present a comparison of time to relapse and cumulative relapse rates between the two treatment groups.

Back to the ACR/ARP 2019 conference hub